Urs Rohner Acquires 473 Shares of GlaxoSmithKline plc (GSK) Stock

GlaxoSmithKline plc (LON:GSK) insider Urs Rohner purchased 473 shares of the stock in a transaction on Wednesday, October 25th. The shares were purchased at an average cost of GBX 1,518 ($19.97) per share, with a total value of £7,180.14 ($9,443.82).

Shares of GlaxoSmithKline plc (GSK) traded down GBX 28.50 ($0.37) during trading hours on Friday, reaching GBX 1,318 ($17.34). 8,310,264 shares of the company traded hands, compared to its average volume of 9,540,000. GlaxoSmithKline plc has a fifty-two week low of GBX 1,315.50 ($17.30) and a fifty-two week high of GBX 1,724.50 ($22.68).

GlaxoSmithKline plc (LON:GSK) last posted its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping analysts’ consensus estimates of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a net margin of 17.79% and a return on equity of 461.88%. The business had revenue of GBX 784.30 billion during the quarter.

The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be given a GBX 19 ($0.25) dividend. This represents a yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.

COPYRIGHT VIOLATION WARNING: “Urs Rohner Acquires 473 Shares of GlaxoSmithKline plc (GSK) Stock” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://stocknewstimes.com/2017/11/11/urs-rohner-buys-473-shares-of-glaxosmithkline-plc-gsk-stock.html.

Several research analysts recently commented on the company. UBS AG set a GBX 1,600 ($21.04) price objective on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, July 26th. Bryan, Garnier & Co reissued a “neutral” rating and issued a GBX 1,710 ($22.49) price objective on shares of GlaxoSmithKline plc in a report on Tuesday, September 19th. Citigroup Inc. reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Thursday. Societe Generale reissued a “sell” rating on shares of GlaxoSmithKline plc in a research note on Thursday. Finally, Liberum Capital restated a “buy” rating and issued a GBX 1,760 ($23.15) target price on shares of GlaxoSmithKline plc in a report on Thursday. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 1,574.25 ($20.71).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply